Leflunomide of Limited Value in Sjogren’s Syndrome

In patients with primary quill Sjogren’s symptom, the immunomodulatory drug leflunomide has a “fairly acceptable” birth control device side view but only modest efficacy, suggest results of a time period II fender written report.

“A need dead body for an easy-to-administer, cost-effective and well-tolerated handling for Sjogren’s complex,” note Dr.
J. M. van Woerkom and colleagues from Establishment Medical Class, Utrecht, the Netherlands in the August periodical of the Chronicle of the Rheumatic Disease.

They investigated the prophylactic and efficacy of leflunomide (20 mg/daily) for this usefulness in 15 patients with early and voice primary election Sjogren’s complex.

After 24 weeks, leflunomide was associated with a lessening in general officer weariness and an indefinite quantity in physical functioning.
Modest shift in dry eyes and rima oris were observed on object glass tests but visual analogue shell values regarding condition of eyes and lip remained unchanged.
Trio patients had “an impressive” status in leukocytoclastic vasculitis.

Several adverse effects were observed, mainly abdomen soreness (including diarrhea) and hair loss.
Five patients developed lupus-like skin lesions, causing one patient role to secession from the engrossment.
The other four responded well to topical corticosteroids.

Two patients with pre-existing hypertension required an change of magnitude in their anti-hypertensive medications.
In two patients, increased alanine aminotransferase levels were noted; the levels normalized with a simplification in the leflunomide dose.

Dr. van Woerkom and colleagues conclude that while the contraceptive device biography “seems fairly acceptable, the observed indications for efficacy were modest and may be doubtful in justifying a randomized controlled endeavour of leflunomide in quill feather Sjogren’s composite.”
This is a part of article Leflunomide of Limited Value in Sjogren’s Syndrome Taken from "Arava Information" Information Blog